

# Letters

## RESEARCH LETTER

### Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the disease it causes, coronavirus disease 2019 (COVID-19), is an emerging health threat.<sup>1</sup> Until February 2020, most cases were described in non-US health systems.<sup>2,3</sup> One of the first deaths in the US was reported at Evergreen Hospital in Kirkland, Washington. Over the following weeks, multiple cases of COVID-19 were identified in the surrounding community and treated at Evergreen Hospital. Most were attributed to US transmission, and the majority were linked to exposures at a skilled nursing facility.

In this case series, we describe the clinical presentation, characteristics, and outcomes of incident cases of COVID-19 admitted to the intensive care unit (ICU) at Evergreen Hospital to inform other clinicians treating critically ill patients with COVID-19.

**Methods** | Patients with confirmed SARS-CoV-2 infection (positive result by polymerase chain reaction testing of a nasopharyngeal sample) admitted to the ICU at Evergreen Hospital between February 20, 2020, and March 5, 2020, were included. Evergreen Hospital is a 318-bed public hospital with a 20-bed ICU serving approximately 850 000 residents of King and Snohomish counties in Washington State.

Prior to data collection, a waiver was obtained from the Evergreen Healthcare institutional review board. Deidentified patient data were collected and analyzed using Stata version 15.1 (StataCorp). Laboratory testing was reviewed at ICU admission and on day 5. Chest radiographs were reviewed by an intensivist and a radiologist. Patient outcome data were evaluated after 5 or more days of ICU care or at the time of death. No analysis for statistical significance was performed given the descriptive nature of the study.

**Results** | A total of 21 cases were included (mean age, 70 years [range, 43-92 years]; 52% male). Comorbidities were identified in 18 cases (86%), with chronic kidney disease and congestive heart failure being the most common. Initial symptoms included shortness of breath (76%), fever (52%), and cough (48%) (Table 1). The mean onset of symptoms prior to presenting to the hospital was 3.5 days, and 17 patients (81%) were admitted to the ICU less than 24 hours after hospital admission.

An abnormal chest radiograph was observed in 20 patients (95%) at admission. The most common findings on initial radiograph were bilateral reticular nodular opacities (11 patients [52%]) and ground-glass opacities (10 [48%]). By 72

Table 1. Baseline Characteristics of 21 Patients With Coronavirus Disease 2019 at Presentation to the Intensive Care Unit

| Baseline characteristics                                       | No. (%) of patients <sup>a</sup> | Reference range |
|--|----------------------------------|-----------------|
| <b>Preadmission comorbidities</b>                              |                                  |                 |
| Asthma   | 2 (9.1)                          |                 |
| Chronic obstructive pulmonary disease                          | 7 (33.3)                         |                 |
| Congestive heart failure                                       | 9 (42.9)                         |                 |
| Diabetes   | 7 (33.3)                         |                 |
| Rheumatologic disease  | 1 (4.8)                          |                 |
| Obstructive sleep apnea  | 6 (28.6)                         |                 |
| Chronic kidney disease   | 10 (47.6)                        |                 |
| End-stage kidney disease                                       | 2 (9.5)                          |                 |
| History of solid organ transplant                              | 2 (9.5)                          |                 |
| Cirrhosis  | 1 (4.8)                          |                 |
| Immunosuppression <sup>b</sup>                                 | 3 (14.3)                         |                 |
| Total with ≥1 comorbidity                                      | 18 (85.7)                        |                 |
| <b>Admission symptoms</b>                                      |                                  |                 |
| Cough  | 11 (47.6)                        |                 |
| Shortness of breath  | 17 (76.2)                        |                 |
| Fever <sup>c</sup>   | 11 (52.4)                        |                 |
| Temperature (range), °C  | 37.6 (35.3-39.2)                 |                 |
| <b>Admission chest radiograph findings<sup>d</sup></b>         |                                  |                 |
| Bilateral reticular nodular opacities                          | 11 (52.4)                        |                 |
| Ground-glass opacities   | 10 (47.6)                        |                 |
| Pleural effusion   | 6 (28.6)                         |                 |
| Peribronchial thickening                                       | 5 (23.8)                         |                 |
| Pleural effusion   | 5 (23.8)                         |                 |
| Focal consolidation  | 4 (19.0)                         |                 |
| Pulmonary edema  | 2 (9.5)                          |                 |
| Venous congestion  | 1 (4.8)                          |                 |
| Atelectasis  | 1 (4.8)                          |                 |
| Clear  | 1 (4.8)                          |                 |
| <b>Admission laboratory measures, mean (range)<sup>a</sup></b> |                                  |                 |
| White blood cell count, /μL                                    | 9365 (2890-16 900)               | 4000-11 000     |
| Absolute lymphocyte count, /μL                                 | 889 (200-2390)                   | 1000-3400       |
| Hemoglobin, g/dL   | 11.4 (8.0-13.7)                  | 11.2-15.7       |
| Platelet count, ×10 <sup>3</sup> /μL                           | 215 (52-395)                     | 182-369         |
| Sodium, mmol/L   | 137 (125-148)                    | 135-145         |
| Creatinine, mg/dL  | 1.45 (0.1-4.5)                   | 0.6-1.2         |
| Total bilirubin, mg/dL   | 0.6 (0.2-1.1)                    | 0-1.5           |
| Alkaline phosphatase, U/L                                      | 80 (41-164)                      | 31-120          |
| Aspartate aminotransferase, U/L <sup>e</sup>                   | 273 (14-4432)                    | 5-40            |
| Alanine aminotransferase, U/L <sup>e</sup>                     | 108 (11-1414)                    | 5-50            |
| Creatinine kinase, U/L   | 95 (45-1290)                     | 21-215          |
| Venous lactate, mmol/L   | 1.8 (0.8-4.9)                    | <1.9            |
| Had troponin level >0.3 ng/mL, No. (%)                         | 3 (14.0)                         |                 |
| Brain-type natriuretic peptide, pg/mL                          | 4720 (69-33 423)                 | <450            |

(continued)

**Table 1. Baseline Characteristics of 21 Patients With Coronavirus Disease 2019 at Presentation to the Intensive Care Unit (continued)**

| Baseline characteristics                  | No. (%) of patients <sup>a</sup> | Reference range |
|---|----------------------------------|-----------------|
| Procalcitonin, ng/mL                      | 1.8 (0.12-9.56)                  | 0.15-2.0        |
| Underwent bronchoalveolar lavage, No. (%) | 7 (33.0)                         |                 |
| After undergoing bronchoalveolar lavage   |                                  |                 |
| White blood cell count, / $\mu$ L         | 515 (174-1222)                   | 0-5             |
| Polymorphonuclear neutrophils, %          | 41.0 (13-77)                     |                 |
| Lymphocytes, %                            | 32.0 (4-90)                      |                 |
| Monocytes, %                              | 39.0 (12-72)                     |                 |

SI conversion factors: To convert absolute lymphocyte count and white blood cell count to  $\times 10^9/L$ , multiply by 0.001; alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, and creatinine kinase to  $\mu$ kat/L, multiply by 0.0167; creatinine to  $\mu$ mol/L, multiply by 76.25; total bilirubin to  $\mu$ mol/L, multiply by 17.104; venous lactate to mg/dL, divide by 0.111.

<sup>a</sup> Unless otherwise indicated.

<sup>b</sup> Defined as outpatient prescription of greater than 10 mg/d of prednisone or an equivalent, use of chemotherapy, or use of nonsteroidal immunosuppressive agents for solid organ transplant or for an autoimmune disease.

<sup>c</sup> Defined as a temperature of greater than 38.0 °C.

<sup>d</sup> Reviewed independently by a chest radiologist and a pulmonary physician.

<sup>e</sup> One patient with a very high admission aspartate aminotransferase and admission alanine aminotransferase skewed the distribution and mean values. At admission the median aspartate aminotransferase level was 34 U/L and the median alanine aminotransferase was 26.5 U/L.

hours, 18 patients (86%) had bilateral reticular nodular opacities and 14 (67%) had evidence of ground-glass opacities. The mean white blood cell count was 9365  $\mu$ L at admission and 14 patients (67%) had a white blood cell count in the normal range. Fourteen patients (67%) had an absolute lymphocyte count of less than 1000 cells/ $\mu$ L. Liver function tests were abnormal in 8 patients (38%) at admission (Table 1).

Mechanical ventilation was initiated in 15 patients (71%) (Table 2). Acute respiratory distress syndrome (ARDS) was observed in 15 of 15 patients (100%) requiring mechanical ventilation and 8 of 15 (53%) developed severe ARDS by 72 hours. Although most patients did not present with evidence of shock, vasopressors were used for 14 patients (67%) during the illness. Cardiomyopathy developed in 7 patients (33%). As of March 17, 2020, mortality was 67% and 24% of patients have remained critically ill and 9.5% have been discharged from the ICU.

**Discussion** | This study represents the first description of critically ill patients infected with SARS-CoV-2 in the US. These patients had a high rate of ARDS and a high risk of death, similar to published data from China.<sup>2</sup> However, this case series adds insight into the presentation and early outcomes in this population and demonstrates poor short-term outcomes among patients requiring mechanical ventilation.

It is unclear whether the high rate of cardiomyopathy in this case series reflects a direct cardiac complication of SARS-CoV-2 infection or resulted from overwhelming critical illness. Others have described cardiomyopathy in COVID-19, and further research may better characterize this risk.<sup>4,5</sup>

**Table 2. Clinical Measures During the Course of Illness and Outcomes of 21 Critically Ill Patients With Coronavirus Disease 2019**

| Clinical measures  | No. (%) of patients <sup>a</sup> |
|--|----------------------------------|
| Acute respiratory distress syndrome (ARDS) <sup>b</sup>                              |                                  |
| None   | 1 (4.8)                          |
| Mild   | 2 (9.5)                          |
| Moderate   | 6 (28.6)                         |
| Severe   | 12 (57.1)                        |
| Ratio of arterial oxygen concentration to the fraction of inspired oxygen (range)    |                                  |
| At admission to ICU  | 169 (69-492)                     |
| At nadir   | 108 (58-247)                     |
| Use of noninvasive positive pressure ventilation                                     | 4 (19.0)                         |
| Use of high-flow oxygen therapy >15 L/min  | 1 (4.8)                          |
| Required mechanical ventilation  | 15 (71.0)                        |
| Among patients requiring intubation for mechanical ventilation                       |                                  |
| Hospital days prior to intubation, mean (range), d                                   | 1.5 (0-12)                       |
| Use of prone positioning for ARDS  | 8 (50.0)                         |
| Use of inhaled epoprostenol for ARDS   | 5 (31.3)                         |
| Use of vasopressors  | 14 (67.0)                        |
| Absolute lymphocyte count at nadir (range), / $\mu$ L                                | 525 (180-1100)                   |
| Evidence of co-infection <sup>c</sup>  |                                  |
| Bacterial  | 1 (4.8)                          |
| Viral  | 3 (14.3)                         |
| Acute kidney failure <sup>d</sup>  | 4 (19.1)                         |
| Cardiomyopathy <sup>e</sup>  | 7 (33.3)                         |
| Acute hepatic injury <sup>f</sup>  | 3 (14.3)                         |
| Seizures   | 1 (4.8)                          |
| Length of follow-up, mean (range), d   | 5.2 (1-10)                       |
| <b>Outcomes</b>  |                                  |
| Died   | 11 (52.4)                        |
| Survived to transfer out of ICU  | 2 (9.5)                          |
| Remains critically ill and requires mechanical ventilation                           | 8 (38.1)                         |
| Length of follow-up for those who survived or remain critically ill, mean (range), d | 7.5 (5-10)                       |

Abbreviation: ICU, intensive care unit.

SI conversion factor: To convert absolute lymphocyte count to  $\times 10^9/L$ , multiply by 0.001.

<sup>a</sup> Unless otherwise indicated.

<sup>b</sup> Definition and severity according to the Berlin Criteria.

<sup>c</sup> One patient developed pseudomonas (bacteremia). Two patients tested positive for influenza A and 1 patient tested positive for parainfluenza type 3.

<sup>d</sup> Defined by criteria from the Kidney Disease Improving Global Outcomes and the International Society of Nephrology.

<sup>e</sup> Defined as evidence of a globally decreased left ventricular systolic function on transthoracic echocardiogram in addition to clinical signs of cardiogenic shock, an elevation in level of creatinine kinase or troponin I, or a decrease in central venous oxygen saturation (<70%) without a past history of systolic dysfunction.

<sup>f</sup> Defined as an alanine aminotransferase or aspartate aminotransferase level greater than 3 times the upper limit of normal.

The limitations of this study include the small number of patients from a single center, that the study population included older residents of skilled nursing facilities, and it is likely

not to be broadly applicable to other patients with critical illness. However, this study provides some initial experiences regarding the characteristics of COVID-19 in patients with critical illness in the US and emphasizes the need to limit exposure of nursing home residents to SARS-CoV-2.

**Matt Arentz, MD**

**Eric Yim, MD**

**Lindy Klaff, MD**

**Sharukh Lokhandwala, MD, MSc**

**Francis X. Riedo, MD**

**Maria Chong, MD**

**Melissa Lee, MD**

**Author Affiliations:** Department of Global Health, University of Washington, Seattle (Arentz); Evergreen Healthcare, Kirkland, Washington (Yim, Klaff, Lokhandwala, Riedo, Lee); Radia Inc, Lynwood, Washington (Chong).

**Corresponding Author:** Matthew Arentz, MD, Department of Global Health, University of Washington, 325 Ninth Ave, Seattle, WA 98104 ([marentz@uw.edu](mailto:marentz@uw.edu)).

**Published Online:** March 19, 2020. doi:[10.1001/jama.2020.4326](https://doi.org/10.1001/jama.2020.4326)

**Author Contributions:** Dr Arentz had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

*Concept and design:* Arentz.

*Acquisition, analysis, or interpretation of data:* Arentz, Yim, Klaff, Lokhandwala, Riedo, Chong, Lee.

*Drafting of the manuscript:* Arentz, Chong.

*Critical revision of the manuscript for important intellectual content:* Arentz, Yim, Klaff, Lokhandwala, Riedo, Lee.

*Statistical analysis:* Arentz, Chong.

*Administrative, technical, or material support:* Riedo.

**Conflict of Interest Disclosures:** None reported.

**Additional Contributions:** We thank Sarah Muni, MD, Michael Bundesmann, MD, and Kristina Mitchell, MD (all with Evergreen Hospital), for their review of the manuscript. They received no compensation for their review. We also acknowledge the clinicians and staff of Evergreen Hospital for their tireless commitment to patient care in the setting of this outbreak.

1. World Health Organization. Coronavirus disease 2019 (COVID-19): situation report 44. Published March 4, 2020. Accessed March 16, 2020. [https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200304-sitrep-44-covid-19.pdf?sfvrsn=783b4c9d\\_2](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200304-sitrep-44-covid-19.pdf?sfvrsn=783b4c9d_2)
2. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. *JAMA*. Published online February 24, 2020. doi:[10.1001/jama.2020.2648](https://doi.org/10.1001/jama.2020.2648)
3. Young BE, Ong SWX, Kalimuddin S, et al; Singapore 2019 Novel Coronavirus Outbreak Research Team. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. *JAMA*. Published online March 3, 2020. doi:[10.1001/jama.2020.3204](https://doi.org/10.1001/jama.2020.3204)
4. Mullen B. COVID-19 clinical guidance for the cardiovascular care team. Published online March 6, 2020. Accessed March 16, 2020. <https://www.acc.org/-/media/665AFA1E710B4B3293138D14BE8D1213.pdf>
5. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. *Nat Rev Cardiol*. 2020. doi:[10.1038/s41569-020-0360-5](https://doi.org/10.1038/s41569-020-0360-5)